CANTICANTI home
Back to diseases

Disease hub

Melanoma

Open Targets catalogue label: melanoma

Melanoma-oriented bucket — evidence tables and trial mirrors are keyword-matched conservatively. This hub is for research navigation, not staging or treatment selection.

Data: Live structured evidence (Supabase)

Source catalogue
13182
Imported rows
—
Explorer-eligible
—
Targets w/ drugs
—
Open guided lookup (general disease context)
Also indexed as

cutaneous melanoma · skin melanoma · malignant melanoma · melanoma · EFO_0000756 · Naevocarcinoma · melanoma, malignant · melanoma (disease) · MONDO:0005105 · OMIM:155755 · ONCOTREE:MEL · MESH:D008545 · OMIM:155600 · ICDO:8720/3 · UMLS:C0025202 · MEDGEN:9944 · UMLS:CN971653 · EFO:0000756 · NANDO:2200077 · KEGG:05218 · HP:0002861 · SCTID:372244006 · NCIT:C3224 · DOID:1909 · Orphanet:411533

Limitations & build flags

  • Read-only structured navigator
  • No clinical outcome benefit inferred
  • Trial presence does not imply success
  • Drug identity may require normalization
  • Terminated/withdrawn trials must remain visible
Disease–target coverage
Coverage metrics for this hub when live evidence-graph and catalogue snapshots are available.
Source catalogue associations
13,182

Open Targets associated-target catalogue count for this disease node — not clinically ranked, validated, or treatment-linked targets.

Measured from Open Targets on 2026-05-15

Imported evidence rows
—

Source evidence rows, not unique targets.

Explorer-eligible targets
—

Targets in the GBM evidence-graph view with default dashboard eligibility.

Targets with drug relationships
—

Distinct active GBM explorer-eligible targets with drug–target mechanism-of-action relationships (disease-scoped; not a global catalogue count).

Disease-linked drugs
—

Unique active drugs linked to this disease in the evidence graph.

Disease-drug evidence edges
—

Active disease–drug evidence edges (methodology detail).

Catalogue and row counts are research inventory signals. They do not mean every association is clinically relevant, validated, druggable, or treatment-linked.